Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
33.60
-0.02 (-0.06%)
Jan 29, 2026, 1:12 PM EST - Market open
Viridian Therapeutics Employees
Viridian Therapeutics had 143 employees as of December 31, 2024. The number of employees increased by 49 or 52.13% compared to the previous year.
Employees
143
Change (1Y)
49
Growth (1Y)
52.13%
Revenue / Employee
$495,028
Profits / Employee
-$1,715,510
Market Cap
3.21B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 143 | 49 | 52.13% | 143 | 0 |
| Dec 31, 2023 | 94 | 8 | 9.30% | 94 | 0 |
| Dec 31, 2022 | 86 | 36 | 72.00% | 86 | 0 |
| Dec 31, 2021 | 50 | 23 | 85.19% | 50 | 0 |
| Dec 31, 2020 | 27 | -19 | -41.30% | 26 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Denali Therapeutics | 517 |
| Beam Therapeutics | 510 |
| Arcutis Biotherapeutics | 342 |
| Xenon Pharmaceuticals | 327 |
| Dyne Therapeutics | 240 |
| Alumis | 223 |
| Catalyst Pharmaceuticals | 181 |
| IDEAYA Biosciences | 131 |
VRDN News
- 20 days ago - Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 23 days ago - Viridian Therapeutics Prepares for Transformational 2026 - Business Wire
- 5 weeks ago - Viridian Therapeutics Announces BLA Acceptance and Priority Review for Veligrotug for the Treatment of Thyroid Eye Disease - Business Wire
- 6 weeks ago - Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit - Benzinga
- 3 months ago - Viridian Therapeutics Is Ready For An Eventful 2026 - Seeking Alpha
- 3 months ago - Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress - Business Wire
- 3 months ago - Viridian Therapeutics Announces Successful October Submission of Biologics License Application (BLA) to U.S. FDA for Veligrotug in Thyroid Eye Disease - Business Wire
- 3 months ago - Viridian Therapeutics Announces Pricing of $251 Million Public Offering of Shares of Common Stock - Business Wire